It is the fourth leading cause of cancer death in our country and has been increasing in recent years. Early diagnosis is difficult, and it is the most difficult cancer to treat, with a 5-year survival rate of around 10%. CA19-9 (Sialyl Lewis A antigen) has long been known as a tumor marker for pancreatic cancer, but there are many false positives, and in about 10% of our country’s population who are Lewis negative (Fut3 is not expressed), the sensitivity is below. This is a problem. Fucosylated haptoglobin is known as a new glycan biomarker for pancreatic cancer [1]. In particular, studies that have performed glycan analysis of site-specific haptoglobin are interesting [2]. When we established a next-generation glycan antibody (an antibody that recognizes both glycans and peptides) against fucosylated haptoglobin and examined its producing organs, it was found to be liver cells around pancreatic cancer cells that had metastasized to the liver and blood cells that had infiltrated around the cancer. Therefore, the fucosylated haptoglobin value (10-7G value) using the next-generation glycan antibody 10-7G can be said to be a glycan biomarker that reflects the cancer microenvironment. Research on new diagnosis and treatment of pancreatic cancer using lectin and development of pig-type glycan vaccines are also being conducted [3]. The strategy of overcoming pancreatic cancer has been shown in Fig. 95.1.